299. Cystic fibrosis
1,592 clinical trials,   1,539 drugs   (DrugBank: 255 drugs),   81 drug target genes,   162 drug target pathways

Searched query = "Cystic fibrosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2012-004491-18-IT
(EUCTR)
07/05/201321/07/2016Safety and Efficacy of Oral BAY 85-8501 in Patients with inflammation of the tubes in the lungs.A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis Non-Cystic Fibrosis Bronchiectasis
MedDRA version: 19.0;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Bayer HealthCare AGNULLNot Recruiting Female: yes
Male: yes
90Phase 2United Kingdom;Italy
2EUCTR2012-004491-18-ES
(EUCTR)
19/02/201321/12/2012Safety and Efficacy of Oral BAY 85-8501 in Patients with inflammation of the tubes in the lungs.A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis Non-Cystic Fibrosis Bronchiectasis
MedDRA version: 14.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Product Name: BAY 85-8501
Product Code: BAY 85-8501
INN or Proposed INN: -
Other descriptive name: BAY 85-8501
Bayer HealthCare AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
90Phase 2aSpain;United Kingdom
3EUCTR2012-004491-18-GB
(EUCTR)
30/01/201318/12/2012Safety and Efficacy of Oral BAY 85-8501 in Patients with inflammation of the tubes in the lungs.A Phase IIa, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety and Efficacy of 28 Day Oral Administration of BAY 85-8501 in Patients with non-Cystic Fibrosis Bronchiectasis Non-Cystic Fibrosis Bronchiectasis
MedDRA version: 15.1;Level: PT;Classification code 10006445;Term: Bronchiectasis;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders ;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
Bayer HealthCare AGNULLNot Recruiting Female: yes
Male: yes
90Phase 2Spain;Italy;United Kingdom